Paul La Rosée

10.2k total citations · 2 hit papers
114 papers, 4.5k citations indexed

About

Paul La Rosée is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Paul La Rosée has authored 114 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Hematology, 55 papers in Genetics and 32 papers in Rheumatology. Recurrent topics in Paul La Rosée's work include Chronic Myeloid Leukemia Treatments (51 papers), Chronic Lymphocytic Leukemia Research (45 papers) and Autoimmune and Inflammatory Disorders Research (32 papers). Paul La Rosée is often cited by papers focused on Chronic Myeloid Leukemia Treatments (51 papers), Chronic Lymphocytic Leukemia Research (45 papers) and Autoimmune and Inflammatory Disorders Research (32 papers). Paul La Rosée collaborates with scholars based in Germany, United States and United Kingdom. Paul La Rosée's co-authors include Andreas Hochhaus, Brian Druker, Michael W. Deininger, Amie S. Corbin, Eric P. Stoffregen, Nicholas C.P. Cross, Rüdiger Hehlmann, Michael B. Jordan, Gritta Janka and Sebastian Kreil and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Paul La Rosée

107 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

2002 675 citations Andreas Hochhaus, Sebastian Kreil et al. Leukemia profile →
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

2019 598 citations Paul La Rosée, AnnaCarin Horne et al. Blood profile →

Peers

Countries citing papers authored by Paul La Rosée

Since Specialization

Citations

This map shows the geographic impact of Paul La Rosée's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul La Rosée with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul La Rosée more than expected).

Fields of papers citing papers by Paul La Rosée

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul La Rosée. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul La Rosée. The network helps show where Paul La Rosée may publish in the future.

Co-authorship network of co-authors of Paul La Rosée

This figure shows the co-authorship network connecting the top 25 collaborators of Paul La Rosée. A scholar is included among the top collaborators of Paul La Rosée based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul La Rosée. Paul La Rosée is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective 2025 ·Leukemia ·Philipp Ernst, Christine M. Lohse, Michael Lauseker, Jan Geißler, (unknown), Tim H. Brümmendorf, Susanne Saußele, Andreas Burchert, Georg‐Nikolaus Franke, Paul La Rosée, Annamaria Brioli, Thomas Schenk, (unknown), Thomas Ernst, (unknown), Andreas Hochhaus	0
2	Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis 2024 ·Leukemia ·(unknown), Thomas Schenk, Thomas Ernst, Ulf Schnetzke, Andreas Hochhaus, Paul La Rosée, Sebastian Birndt	16
3	Value of hemophagocytosis in the diagnosis of hemophagocytic lymphohistiocytosis in critically ill patients 2024 ·European Journal Of Haematology ·Peter Nyvlt, Friederike S. Schuster, Jana Ihlow, (unknown), Claudia Spies, (unknown), Thomas Schenk, (unknown), Jörg Westermann, Frank M. Brunkhorst, Paul La Rosée, Gritta Janka, (unknown), Gunnar Lachmann	2
4	The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial 2023 ·Leukemia ·Johanna Hammersen, Sebastian Birndt, Konstanze Döhner, Philipp A. Reuken, Andreas Stallmach, (unknown), (unknown), Markus Pfirrmann, (unknown), (unknown), Karl Träger, Hinrich Bremer, Salvatore Russo, Gerald Illerhaus, Daniel Drömann, Sven Schneider, Paul La Rosée, Andreas Hochhaus	11
5	Paraneoplastische Hyperleukozytose bei Lungenkarzinom 2022 ·Die Innere Medizin ·(unknown), (unknown), (unknown), Frank Schaumann, (unknown), Frank A. Schmid, Jörg Kalla, (unknown), Hinrich Bremer, Paul La Rosée	0
6	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation 2020 ·Leukemia ·(unknown), Hinrich Bremer, Iris Gehrke, (unknown), Andreas Hochhaus, Sebastian Birndt, M. Fellhauer, (unknown), Bernhard Kumle, Salvatore Russo, Paul La Rosée	158
7	Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry 2020 ·Journal of Cancer Research and Clinical Oncology ·Sebastian Birndt, Thomas Schenk, (unknown), Frank M. Brunkhorst, Georg Maschmeyer, Frank Rothmann, Thomas Weber, Markus Müller, Jens Panse, Olaf Penack, Roland Schroers, Jan Braess, Norbert Frickhofen, Stephan Ehl, Gritta Janka, Kai Lehmberg, Mathias W. Pletz, Andreas Hochhaus, Thomas Ernst, Paul La Rosée	69
8	Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore 2020 ·Critical Care ·Cornelia Knaak, Peter Nyvlt, Friederike S. Schuster, Claudia Spies, (unknown), Thomas Schenk, Felix Balzer, Paul La Rosée, Gritta Janka, Frank M. Brunkhorst, Didier Keh, Gunnar Lachmann	81
9	Recommendations for the management of hemophagocytic lymphohistiocytosis in adults breakdown → 2019 ·Blood ·Paul La Rosée, AnnaCarin Horne, Melissa Hines, Tatiana von Bahr Greenwood, Rafał Machowicz, Nancy Berliner, Sebastian Birndt, Juana Gil-Herrera, Michael Girschikofsky, Michael B. Jordan, Ashish Kumar, Jan van Laar, Gunnar Lachmann, Kim E. Nichols, Athimalaipet V Ramanan, Yini Wang, Zhao Wang, Gritta Janka, Jan‐Inge Henter	598
10	Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society 2018 ·The Journal of Allergy and Clinical Immunology In Practice ·Stephan Ehl, Itziar Astigarraga, Tatiana von Bahr Greenwood, Melissa Hines, AnnaCarin Horne, Eiichi Ishii, Gritta Janka, Michael B. Jordan, Paul La Rosée, Kai Lehmberg, Rafał Machowicz, Kim E. Nichols, Elena Sieni, Zhao Wang, Jan‐Inge Henter	118
11	A consensus review on malignancy‐associated hemophagocytic lymphohistiocytosis in adults 2017 ·Cancer ·Naval Daver, Kenneth L. McClain, Carl E. Allen, Sameer A. Parikh, Zaher K. Otrock, Cristhiam M. Rojas‐Hernandez, Boris Blechacz, Sa Wang, Milen Minkov, Michael B. Jordan, Paul La Rosée, Hagop M. Kantarjian	143
12	Rheumatische Krankheitserscheinungen bei hämatologischen Neoplasien 2017 ·Zeitschrift für Rheumatologie ·Stefan Kleinert, Paul La Rosée, K. Krüger	0
13	The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia 2007 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Georgia Metzgeroth, Beate Schultheis, Christian Kühn, Alexandra Dorn‐Beineke, Paul La Rosée, Rüdiger Hehlmann, Jan Hastka	9
14	Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib 2006 ·Clinical Cancer Research ·Paul La Rosée, Taiping Jia, (unknown), Nicolai Härtel, Peter de Vries, Lynn Bonham, David Hollenback, Jack W. Singer, Junia V. Melo, Brian Druker, Michael W. Deininger	23
15	Systemic mastocytosis simulating osseous metastatic disease 2006 ·British Journal of Haematology ·Georgia Metzgeroth, Dietmar Dinter, Philipp Erben, Paul La Rosée, Rüdiger Hehlmann, Jan Hastka	3
16	Lack of clinical efficacy of imatinib in metastatic melanoma 2005 ·British Journal of Cancer ·Selma Ugurel, Ralf Hildenbrand, (unknown), Paul La Rosée, Peter Paschka, Antje Sucker, Petra Keikavoussi, Jürgen C. Becker, Werner Rittgen, Andreas Hochhaus, Dirk Schadendorf	180
17	No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec™/Glivec®) 2003 ·The Hematology Journal ·Paul La Rosée, Lei Shen, Eric P. Stoffregen, Michael W. Deininger, Brian Druker	15
18	Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective 2002 ·Leukemia ·Paul La Rosée, Michael O’Dwyer, Brian Druker	74
19	Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy 2001 ·ePrints Soton (University of Southampton) ·Sebastian Kreil, Martin Müller, Tanja Lahaye, Paul La Rosée, A. Corbin, Claudia Schoch, Nicholas C.P. Cross, Ute Berger, Harald Rieder, Brian Druker, Harald Gschaidmeier, R. Hehlmann, Andreas Hochhaus	16
20	Desensitization of the pulmonary adenylyl cyclase system 1999 ·Journal of the American College of Cardiology ·Mathias M. Borst, (unknown), Carsten Schwencke, Paul La Rosée, Rainer Marquetant, Markus Haass, W. Kübler, Ruth H. Strasser	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact